Carol Gallagher joined NEA in October 2014. She is primarily focused on making biopharma investments. Carol is a proven entrepreneur, operator and more recently investor with over 30 years of experience in commercial, drug development and business development roles. Prior to joining NEA she was a Venture Partner with Frazier Healthcare and she served as an independent director on multiple Boards. From 2008-2011, Carol was president and CEO of Calistoga Pharmaceuticals which developed the first-in-class therapeutic now marketed by Gilead as ZYDELIG.

She currently serves as a director at AtaraBio, Chromacode, Millendo, PIONYR Immunotherapeutics, Qpex BioPharma, and Turning Point Therapeutics.